WINTON GROUP Ltd Makes New $3.26 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

WINTON GROUP Ltd acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, Holdings Channel reports. The firm acquired 41,911 shares of the medical device company’s stock, valued at approximately $3,259,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Motley Fool Asset Management LLC lifted its stake in DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after acquiring an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new position in shares of DexCom during the fourth quarter worth $3,334,000. Congress Asset Management Co. increased its holdings in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in DexCom by 2,226.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after buying an additional 222,548 shares during the last quarter. Finally, MayTech Global Investments LLC boosted its position in shares of DexCom by 53.6% during the 3rd quarter. MayTech Global Investments LLC now owns 259,257 shares of the medical device company’s stock worth $17,381,000 after acquiring an additional 90,498 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM opened at $69.47 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $82.65 and its two-hundred day moving average is $77.02. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99. The firm has a market capitalization of $27.15 billion, a PE ratio of 48.58, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of several recent analyst reports. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group upped their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Cfra Research upgraded shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.